LAWRENCE, Mass., Nov. 1, 2017 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced new findings in a series of compelling research abstracts demonstrating, and further validating, the importance of more frequent home hemodialysis.
"NxStage is represented by 11 accepted abstracts evaluating home hemodialysis, treatment frequency, and peritoneal dialysis," said Joe Turk, President, NxStage Medical, Inc. "Additionally, we are thrilled that a total of 33 abstracts about home hemodialysis and hemodialysis frequency are being evaluated and discussed at such an important congress."
The collection of data will be presented at the American Society of Nephrology (ASN) Congress being held October 31 – November 5, 2017, in New Orleans, LA.
Two oral presentations confirm findings from previously published interim analyses of the FREEDOM study of daily home hemodialysis: specifically, that frequent home hemodialysis coincided with dramatic reductions in post-treatment recovery time and broad improvements in both physical and mental health-related quality of life. Another abstract finds that nocturnal home hemodialysis is associated with greater retention of home hemodialysis patients compared to daytime treatment. Four other oral presentations will also address aspects of home hemodialysis and hemodialysis frequency.
"Data continues to affirm the benefits of frequent home hemodialysis by showing continued improvements in patient-centered outcomes," said, Dr. Eric Weinhandl, PhD, MS, NxStage Clinical Epidemiologist and Adjunct Assistant Professor of Pharmaceutical Care & Health Systems at the University of Minnesota. "We are excited to be sharing this data at ASN Kidney Week and to continue the conversation about the importance of individualized dialysis therapy and improving access to therapy in the home."
Five posters will also be presented, including data that demonstrate higher home hemodialysis training graduation rates in patients using the Nx2me Connected Health® iPad® application.
Oral presentations will be made by experts in the industry on both Thursday, November 2, in Room 290 beginning at 4:30 PM and Friday, November 3, Room 295, beginning at 4:30 PM.
Full abstracts can be read online at https://www.asn-online.org/abstracts/.
Conference attendees can also meet with NxStage representatives in booth 1127 to discuss the most recent publications.
Visit www.NxStage.com for more information about therapy options with the NxStage® System One™.
The NxStage System One is a prescription device and, like all medical devices, involves some risks. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream, and blood loss due to clotting or accidental disconnection of the blood tubing set. Patients should consult with their doctor to understand the risks and responsibilities of home and/or more frequent hemodialysis using the NxStage System One. Additionally, the reported benefits of home and/or more frequent hemodialysis may not be experienced by all patients. Patients and providers are encouraged to contact their state regulators to discuss state-specific regulations that may impact dialysis in the skilled nursing facility setting.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis, home nocturnal hemodialysis and solo home hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners (or for patients prescribed to receive solo dialysis, alone), where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. In addition, NxStage's Nx2me Connected Health platform collects important NxStage System One and patient information for flexible viewing, monitoring and reporting that may improve patient management and patient retention, as well as simplify alternative site care. www.nxstage.com.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical technology company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. NxStage also has established a small number of dialysis clinics committed to the development of innovative care delivery models for patients with ESRD. For more information on NxStage and its products and services, please visit the Company's websites at www.nxstage.com and www.nxstagekidneycare.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen K. Sheppard, Esq.
View original content with multimedia:http://www.prnewswire.com/news-releases/eleven-unique-nxstage-abstracts-accepted-for-2017-kidney-week-300547757.html
SOURCE NxStage Medical, Inc.